Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.